57381-36-9Relevant articles and documents
CRYSTALLINE ALK5 INHIBITORS AND USES THEREOF
-
Paragraph 0294; 0296, (2021/12/29)
The present disclosure provides crystalline forms of activin receptor-like kinase 5 (ALK5) inhibitors. Also disclosed are pharmaceutical compositions comprising the crystalline forms, methods of using the crystalline forms to modulate the activity of ALK5 and methods of treating disorders mediated by ALK5 using the crystalline forms.
Preparation method of halogenated benzothiazepine compound as well as product prepared by preparation method and application of halogenated benzothiazepine compound
-
Paragraph 0052-0056; 0072-0076; 0077-0079; 0082-0083, (2020/09/02)
The invention discloses a preparation method of a halogenated benzothiazepine compound as well as a product prepared by the preparation method and an application of the halogenated benzothiazepine compound, and relates to the technical field of chemical s
NEW COMPOUNDS
-
Page 139, (2010/02/06)
The present invention relates to new compounds of formula I, (I) a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.